NCT04983264View on ClinicalTrials.gov

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

December 6, 2022

Study Completion Date

December 6, 2022

Conditions
Sickle Cell Disease
Interventions
DRUG

GBT021601

Tablets and capsules which contain GBT021601 drug substance

Trial Locations (3)

30329

Visionaries Clinical Research LLC, Atlanta

30342

Children's Healthcare of Atlanta AFLAC Center, Atlanta

33147

Advanced Pharma CR, LLC, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04983264 - A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD) | Biotech Hunter | Biotech Hunter